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Study subjects
All study subjects were of Caucasian descent. We screened for polymorphisms in 10 subjects with hypertriglyceridemia and 10 clinically normal subjects. The 10 screened hypertriglyceridemic subjects were a random subset of 120 unrelated dyslipidemic subjects (63 women), who had mean (Ϯstandard deviation) age, body mass index, plasma total cholesterol and high-density lipoprotein cholesterol, and plasma triglyceride level of 51.3 Ϯ 12.4 years, 33.0 Ϯ 5.2 kg/ m 2 , 7.51 Ϯ 2.52 mmol/l, 1.04 Ϯ 0.23 mmol/l, and 6.88 ϩ 5.56 mmol/l, respectively. The 10 screened normolipidemic subjects came from a sample of 137 age-and sex-matched normolipidemic unrelated matched subjects of Caucasian descent for calculation of polymorphism allele frequencies. The University of Western Ontario Ethics Review Panel approved the study.
Screening candidate genes by DNA sequencing To amplify coding regions and intron-exon boundaries, we characterized intron-exon boundaries for all exons except exon 1 using GenBank accession numbers 13644358 and AF035268. Amplification primers were then designed to include at least 50 nucleotides within each intron at each intron-exon boundary, and primer sequences are shown in Table 1 . Amplification conditions for all reactions were 94°C for 5 min, followed by 30 cycles of 30 s each of denaturation at 94°C, followed by a unique annealing temperature (Table 1 ) and extension at 72°C, and ending with a final single 10-min extension step at 72°C. Purified amplification fragments were sequenced using an Applied Biosystems Prism 377 Automated DNA Sequencer (Mississauga, Ontario, Canada), and electropherograms were interpreted using Sequence Navigator software (version 1).
Introduction
Phosphatidylserine-specific phospholipase A1 (PSPLA1), a serine phospholipid-specific phospholipase, was initially cloned from rat platelets (Sato et al. 1997) . Although PSPLA1 belongs to the phospholipase gene family, the predicted amino acid sequence of the gene product demonstrated greater homology with mammalian triglyceride lipases than with phospholipases (Sato et al. 1997) . Human PSPLA1 was cloned and mapped to chromosome 3q13.13-13.2 (Nagai et al. 1999) , and the murine homolog was cloned and mapped to mouse chromosome 16 (Wen et al. 2001) . To have tools to evaluate a possible role for PSPLA1 in lipoprotein or metabolic disorders, we characterized intronexon boundaries of human PSPLA1, developed primers to amplify coding regions of PSPLA1 from genomic DNA, and discovered nine DNA polymorphisms.
Polymorphism genotyping
Genotypes of all PSPLA1 polymorphisms were determined from electropherogram tracings of direct sequencing experiments in subsamples of 40 control subjects and 40 dyslipidemic subjects, using specific amplification conditions for the culprit exon as outlined earlier and in Table 2 . Chi-square analysis was used to assess deviation of genotype frequencies from Hardy-Weinberg expectations, and to compare frequencies of the single-nucleotide polymorphism (SNP) in the dyslipidemic and normal samples. This sample size afforded 74% power (alpha ϭ 0.05, two-sided) to detect a 2.5-fold difference in allele frequency between cases and controls for allele frequency of 0.2. For the 360GϾA (R110H) SNP, all 120 dyslipidemic subjects and 137 normolipidemic control subjects were genotyped using direct genomic DNA sequencing. This sample size afforded 74% power (alpha ϭ 0.05, two-sided) to detect a 2.5-fold 
Results
Identification of PSPLA1 polymorphisms. PSPLA1 genomic structure and position of polymorphisms are shown in Fig. 1 . Genomic DNA sequencing experiments in normal controls and dyslipidemic subjects uncovered nine PSPLA1 polymorphisms (Table 2 ). There were five coding sequence and four noncoding sequence polymorphisms ( Table 2) . The observed frequency of each genotype did not deviate from Hardy-Weinberg expectations (all P Ͼ 0.50). Caucasian allele frequencies from subsets of 40 normolipidemic subjects and 40 dyslipidemic subjects are shown. The allele frequencies were not significantly different (all P Ͼ 0.40). In an expanded analysis of 120 subjects with dyslipidemia and 137 normal subjects, the 360A allele frequency was 0.033 in dyslipidemic subjects and 0.045 in normolipidemic subjects (P ϭ 0.65).
Discussion
Hypertriglyceridemia and associated lipoprotein abnormalities are important determinants of atherosclerosis (Busch and Hegele 2000) . Although mutations in the genes encoding lipoprotein lipase and hepatic lipase underlie some rare familial syndromes, the molecular defects in most patients with elevated triglycerides are unknown (Busch and Hegele 2000) . PSPLA1 is an interesting candidate gene for plasma triglyceride variation, based on its homology with other human triglyceride lipases (Nagai et al. 1997; Sato et al. 1999 ). Our findings suggest that variation in PSPLA1 is not associated with hypertriglyceridemia, although the sample size we studied was admittedly relatively small. Much larger sample sizes may be required to detect more modest associations, especially for polymorphisms whose minor allele frequency is low. The identification of amplification primers and DNA polymorphisms provides tools for a more systematic assessment of the association between variation in PSPLA1 and plasma triglycerides, or related metabolic traits. The DNA polymorphisms also provide tools for mapping studies of chromosome 3q13.13-13.2. 
